Indeed, we observed that the application of the CXCR2 inhibitor in the adjuvant setting after resection of primary melanomas diminished the number of macroscopic metastatic nodules in lungs and liver and markedly prolonged mouse survival. The gene discussed is CXCR2; the disease is melanoma.